[Abstract Only] Randomized Trial: Triplet-targeted Therapy Improves Survival in BRAF Mutated Advanced Colorectal Cancer
4 Oct, 2019 | 07:24h | UTCEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations – University of Texas MD Anderson Cancer Center (free)